SpringerLink
Log in

Monoclonal Antibodies Recognizing Melanoma-Associated Antigens.

  • Chapter
Application of Monoclonal Antibodies in Tumor Pathology

Part of the book series: Developments in Oncology ((DION,volume 50))

  • 51 Accesses

Abstract

Cutaneous melanoma accounts for roughly 1% of cancers in the United States (1). It has been reported repeatedly that its incidence in western countries is rising rapidly (1). Accordingly, its mortality is rising, but less rapidly than its incidence because an increasing proportion of cases is diagnosed in an early phase of tumor growth. The most common types of cutaneous melanoma are superficial spreading melanoma (SSM), nodular melanoma (NM) and lentigo malignant melanoma (LMM). In SSM and LMM early melanomas show a horizontal (radial) growth pattern (1). More advanced tumors show superimposed a vertical growth pattern as a result of further neoplastic progression (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

eBook
USD 9.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Mastrangelo MJ, Baker AR and Katz HR. Cutaneous melanoma. In De Vita VT, Hellman S and Rosenberg SA (eds.): Cancer, Principles and practice of oncology. 1985; pp. 1371–1442, Lippincott, Philadelphia.

    Google Scholar 

  2. Clark Jr. WH, Reimer RR, Greene M. Origin of familial melanoma from heriditable melanocytic lesions the BK mole syndrome. Arch. Dermatol. 1978; 114: 732–38.

    Article  PubMed  Google Scholar 

  3. Bröcker E-B, Suter L, Brüggen J, Ruiter DJ, Macher E, Sorg C. Phenotypic dynamics of tumor progression in human malignant melanoma. Int. J. Cancer 1985; 36: 29–35.

    Article  PubMed  Google Scholar 

  4. Natali PG, Cordiali-Fei P, Cavaliere R, Difilippo F, Quaranta V, Pellegrino MA and Ferrone S. Ia-like antigens on freshly explanted human malignant melanoma. Clin. Immunol. Immunopathol. 1981; 19: 250–9.

    Article  PubMed  CAS  Google Scholar 

  5. Ruiter DJ, Bhan AK, Harrist TJ, Sober AJ and Mihm Jr. MC. Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J. Immunol. 1982; 129: 2808–15.

    PubMed  CAS  Google Scholar 

  6. Damjanov J, Knowles BB. Biology of Disease. Monoclonal antibodies and tumor-associated antigens. Lab. Invest. 1983; 48: 510–25.

    PubMed  CAS  Google Scholar 

  7. Vennegoor C, Calafat J, Hageman Ph. Van Buitenen F, Janssen H, Kolk A, Rümke Ph. Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C3. Int. J. Cancer 1985; 35: 287–295.

    Article  PubMed  CAS  Google Scholar 

  8. Van Duinen SG, Ruiter DJ, Hageman Ph, Vennegoor C, Dickersin GR, Scheffer E, Rümke Ph. Immunohistochemical and histochemical tools in the diagnosis of amelanotic melanoma. Cancer 1984; 53: 1566–73.

    Article  PubMed  Google Scholar 

  9. Nakajima T, Watanabe S, Sato Y, Kameyo T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 1981; 50: 912–8.

    Article  Google Scholar 

  10. Atkinson B, Ernst CS, Ghrist BFD, Herly M, Blaszcyk M, Ross AH, Herlyn D, Steplewski Z, Koprowski H. Identification of melanoma-associated antigens using fixed tissue screening fo antibodies. Cancer Res. 1984; 44: 2577–81.

    PubMed  CAS  Google Scholar 

  11. Natali PG, Imai K, Wilson BS, Bigotti A, Cavaliere R, Pellegrino MA, Ferrone S. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J. Natl. Cancer Inst. 1981; 67: 591–5.

    PubMed  CAS  Google Scholar 

  12. Wilson BS, Imai K, Natali PG, Ferrone S. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int.J. Cancer 1981; 28: 293–300.

    Article  PubMed  CAS  Google Scholar 

  13. Garrigues HJ, Tilgen W, Hellstrom I, Franke W, Hellström KE. Detection of a human melanoma-associated antigen, p97 in histological sections of primary human melanomas. Int. J. Cancer 1982; 29: 511–5.

    Article  PubMed  CAS  Google Scholar 

  14. Dippold WG, Dienes HP, Knuth A, Meijer zum Büschenfelde K-H. Immunohistochemical localization of ganglioside GD3 in human malignant melanoma, epithelial tumors and normal tissues. Cancer Res. 1985; 45: 3699–3706.

    PubMed  CAS  Google Scholar 

  15. Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ. Surace antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificty analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 1985; 45: 4401–11.

    PubMed  CAS  Google Scholar 

  16. Suter L, Bröcker E-B, Brüggen J, Ruiter DJ, Sorg C. Heterogeneity of primary and metastatic human malignant melanoma as detected with monoclonal antibodies in cryostat sections of biopsies. Cancer Immunol. Immunother. 1983; 16: 53–8.

    Article  PubMed  CAS  Google Scholar 

  17. MacKie RM, Campbell J, Turbitt ML. Use of NKI/C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J. Clin. Pathol. 1984; 37: 367–72.

    Article  PubMed  CAS  Google Scholar 

  18. Palmer AA, Hall BE, Lew M. A comparison of some methods for identifying amelanotic and oligomelanotic melanoma metastases in paraffin sections. Pathology 1985; 17: 335–9.

    Article  PubMed  CAS  Google Scholar 

  19. Hagen EC, Vennegoor C, Schlingemann RO, Van der Velde EA, Ruiter DJ. Correlation of histopathological characteristics with staining patterns in human melanoma assessed by monoclonal antibodies reactive on paraffin sections. Histopathology 1986 (in press).

    Google Scholar 

  20. GatterKC, Ralfkiaer E, Skinner J. Brown D, Heryet A, Pulford KAF, Hou-Jensen K, Mason DY. An immunocytochemical study of malignant melanoma and its differntial diagnosis from other malignant tumours. J. Clin. Pathol. 1985; 38: 1353–7.

    Article  Google Scholar 

  21. Chung EB, Enzinger FM. Malignant melanoma of soft parts. A reassessment of clear cell sarcoma. Am. J. Surg. Pathol. 1983; 7: 405–13.

    Article  PubMed  CAS  Google Scholar 

  22. Stefansson K, Wollmann R, Jerkovic M. S100 protein in soft-tissue tumors derived from Schwann cells and melanocytes. Am. J. Pathol. 1982; 106: 261–8.

    PubMed  CAS  Google Scholar 

  23. Kahn HJ, Marks A, Thorn H, Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am. J. Pathol. 1983; 79: 341–7.

    CAS  Google Scholar 

  24. Kindblom L-G, Lodding P, Rosengren L, Bandier J, Haglid K. S100 protein in melanocytic tumors. Acta Pathol. Microbiol. Scand. Sect A. 1984; 92: 219–30.

    CAS  Google Scholar 

  25. Moore B. Chemistry and biology of the two proteins S100 and 14-3-2 specific to the nervous system. Int. Rev. Neurobiol. 1972; 15: 215–25.

    Article  PubMed  CAS  Google Scholar 

  26. Bumol TF and Reisfeld RA. Unique glyocprotein-proteoglycan complex defined by a monoclonal antibody on human melanoma cells. Proc. Natl. Acad. Sci. USA, 1982; 79: 1245–49.

    Article  PubMed  CAS  Google Scholar 

  27. Woodbury RG, Brown JP, Yeh MY, Hellström I, Hellström K-E. Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. Proc. Natl. Acad. Sci., USA, 1980; 77: 2183–87.

    Article  PubMed  CAS  Google Scholar 

  28. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3 - a prominent ganglioside of human melanoma: detection and characterization by mouse monoclonal antibody. J. Exp. Med. 1982; 155: 1133–47.

    Article  PubMed  CAS  Google Scholar 

  29. Suter L, Brüggen J, Bröcker E-B, Sorg C. A tumor-associated antigen expressed in melanoma cells with lower malignant potential. Int. J. Cancer 1985; 35: 787–91.

    Article  PubMed  CAS  Google Scholar 

  30. Holzmann B, Johnson JP, Kaudewitz P, Riethmüller G. In situ analysis of antigens on malignant and benign cells of the melanocyte lineage: differential expression of two surface molecules, gp75 and p89. J. Exp. Med. 1985; 161: 366–77.

    Article  PubMed  CAS  Google Scholar 

  31. Ruiter DJ, Dingjan M, Steijlen PM, Van Beveren-Hooijer M, De Graaff-Reitsma CB, Bergman W, Van Muyen GNP, Warnaar SO. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi. J. Invest. Dermatol. 1985; 85: 4–8.

    Article  PubMed  CAS  Google Scholar 

  32. Imam A, Mitchell MS, Modlin RL, Taylor CR, Kempf RA, Kan-Mitchell J. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections. J. Invest. Dermatol. 1986; 86: 145–8.

    Article  PubMed  CAS  Google Scholar 

  33. De Vries JE, Keizer GD, Te Velde AA, Voordouw A, Ruiter DJ, Figdor CG. A melanoma-associated cellular adhesion molecular (MACAM-1) involved in the adhesion, motility and migration of melanoma cells. Int. J. Cancer 1986; in press.

    Google Scholar 

  34. Natali PG, Cordiali-Fei P, Cavaliere R, DiFilippo F, Quaranta V, Pellegrino MA, Ferrone S. Ia-like antigens on freshly explanted human malignant melanoma. Clin. Immunol. Immunopathol. 1981; 19: 250–9.

    Article  PubMed  CAS  Google Scholar 

  35. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S. DR (Ia-like) antigens on human melanoma cells: Serological detection and immunological characterization. J. Exp. Med. 1979; 149: 658–68.

    Article  PubMed  CAS  Google Scholar 

  36. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, Van Vloten WA, Russo C, Ferrone S. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res. 1984; 44: 3930–5.

    PubMed  CAS  Google Scholar 

  37. Brown JP, Heurick RM, Hellström I, Hellstrom KE, Doolittle RF, Dreyer WJ. Human melanoma-associated antigen p97 is structurally and funtionally related to transferrin. Nature 1982; 296: 171–3.

    Article  PubMed  CAS  Google Scholar 

  38. Ruiter DJ, Van Muyen GNP, Warnaar SO. Monoclonal antibodies in diagnostic tumor pathology. In: Biotechnology in Diagnostics. H. Koprowski, S. Ferrone, A. Albertini (eds.). Elsevier Science Publ. BV, Amsterdam, 1985; pp. 31–43.

    Google Scholar 

  39. Hellström KE, Hellström I. Monoclonal anti-melanoma antibodies and their possible clinical use. In: Monoclonal antibodies for cancer detection and therapy. R.W. Baldwin, V.S. Byers (eds), Academic Press, London 1985; pp. 17–51.

    Google Scholar 

  40. Elder DE. Editorial: Distinguishing cancer and noncancer. J. Invest. Dermatol. 1985; 85: 1–3.

    Article  PubMed  CAS  Google Scholar 

  41. Dantas ME, Brown JP, Thomas MR, Robinson WA, Glode LM. Detection of melanoma cells in bone marrow using monoclonal antibodies. Cancer 1983; 52: 949–53.

    Article  PubMed  CAS  Google Scholar 

  42. Cochran AJ, Wen D-R, Herschman HR. Occult melanoma in lymph nodes detected by antiserum to S100 protein. Int. J. Cancer 1984; 34: 159–63.

    Article  PubMed  CAS  Google Scholar 

  43. Bröcker E-B, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J. Invest. Dermatol. 1984; 82: 244–7.

    Article  PubMed  Google Scholar 

  44. Rode J, Dhillon AP. Neuron specific enolase and S100 protein as possible prognostic indicators in melanoma. Histopathology 1984; 8: 1041–52.

    Article  PubMed  CAS  Google Scholar 

  45. Van Duinen SG, Ruiter DJ, Brocker E-B, Sorg C, Welvaart K, Ferrone S. Association of low level of HLA-ABC antigens or high level of Ia antigens in metastatic melanoma with a high grade of malignancy. J. Invest. Dermatol. 1984; 82: 558.

    Google Scholar 

  46. Van Duinen SG, Ruiter DJ, Ferrone S. Associated expression of HLA class I and class II antigens on melanoma cells in surgically removed metastases. J. Pathol, (in press)

    Google Scholar 

  47. Ruiter DJ, Van Duinen SG, Bröcker E-B, Schrier PI, Welvaart K, Ferrone S. Low level of class I or high level of class II Major Histocompatibility Complex antigens in metastatic melanoma is associated with a high grade of malignancy. Proc. Amer. Ass. Cancer Res. 1985; 26: 315.

    Google Scholar 

  48. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J. Am. Statistic. Assoc. 1958; 53: 457–8.

    Article  Google Scholar 

  49. Holden CA, Sanderson AR, MacDonald DM. Absence of human leukocyte antigen molecule in skin tumors and some cutaneous appendages: evidence using monoclonal antibodies. J. Am. Acad. Dermatol. 1983; 9: 867–71.

    Article  PubMed  CAS  Google Scholar 

  50. Kawabat SE, Bast Jr RC, Knapp RC; Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int. J. Cancer 1983; 32: 547–54.

    Article  Google Scholar 

  51. Dennis JW, Donaghue TP, Carlow DA, Kerbel RS. Demonstration of a correlation between tumor cell H-2 antigen content, immunogenicity, and tumorigenicity using lectin-resistant tumor variants. Cancer Res. 1981; 41: 4010–9.

    PubMed  CAS  Google Scholar 

  52. Schrier PI, Bernhards R, Vaessen RTMJ, Houweling A, Van der Eb AJ. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 1983; 305: 771–5.

    Article  PubMed  CAS  Google Scholar 

  53. Bernhards R, Schrier PI, Houweling A, Bos JL, Van der Eb AJ, Zijlstra M, Melief CJM. Tumorigenicity of cells transformed by adenovrius type 12 by evasion of T-cell immunity. Nature 1983; 305: 776–9.

    Article  Google Scholar 

  54. Sanderson AR, Beverley PCL. Interferon, B2-microglobulin and immunoselection in the pathway to malignancy. Immunology Today 1983; 4: 211–3.

    Article  CAS  Google Scholar 

  55. Ruiter DJ, Bröcker E-B, Jager M, Koning F, Schrier PI, Ferrone S. HLA-DR and HLA-DQ expression in cutaneous melanoma. J. Invest. Dermatol. 1985; 84: 442.

    Google Scholar 

  56. Fossati G, Taramelli D, Balsari A, Bogdanovich G, Andreola S, Parmiani G. Primary but not metastatic human melanomas expressing DR antigens stimulate autologous lymphocytes. Int. J. Cancer 1984; 33: 591–7.

    Article  PubMed  CAS  Google Scholar 

  57. Guerry IV D, Alexander MA, Herlyn MF, Zehngebot LM, Mitchell KF, Zmijewski CM. Lusk EJ. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J. Clin. Invest. 1984; 73: 267–71.

    Article  PubMed  Google Scholar 

  58. Taramelli D, Fossati G, Balsari A, Marolda R, Parmiani G. The inhibition of lymphocyte stimulation by autologous human metatastic melanoma cells correlates with the expression of HLA-DR antigens on the tumor cells. Int. J. Cancer 1984; 34: 797–806.

    Article  PubMed  CAS  Google Scholar 

  59. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. J. Exp. Med. 1982; 156: 1755–66.

    Article  PubMed  CAS  Google Scholar 

  60. Galloway DR, McGabe RP, Pellegrino MA, Ferrone S, Reisfeld RA. Tumor associated antigens in spent medium of human melanoma cells: immunochemical characteristization with xenoantisera. J. Immunol. 1981; 126: 62–6.

    PubMed  CAS  Google Scholar 

  61. Giacomini P, Veglia F, Fei PC, Rehle T, Natali PG, Ferrone S. Level of a membrane-bound high molecular weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res. 1984; 44: 1281–87.

    PubMed  CAS  Google Scholar 

  62. Ross AH, Herlyn M, Ernst CS, Guerry D, Bennicelli J, Ghrist BFD, Atkinson B, Koprowsky H. Immuno-assay for melanoma-associated proteoglycan in the sera of patients using monoclonal and polyclonal antibodies. Cancer Res. 1984; 44: 4642–47.

    PubMed  CAS  Google Scholar 

  63. Morgan AC, Crane MM, Rossen RD. Measurement of a monoclonal antibody-defined, melanoma-associated antigen in human sera: correlation of circulating antigen levels with tumor burden. J. Natl. Cancer Inst. 1984; 72: 243–48.

    PubMed  Google Scholar 

  64. Oldham RK, Foon KA, Morgan AC, Woodhouse CS, Schroff RW, Abrams PG, Fer M, Schoenberger CS, Farral M, Kimball E, Sherwin SA. Monoclonal antibody therapy of malignant melanoma: in vivo localization in cutaneous metastasis after intravenous administration. J. Clin. Oncol. 1984; 2: 1235–44.

    PubMed  CAS  Google Scholar 

  65. Schroff RW, Woodhouse CS, Foon KA, Oldham RK, Farrell MM, Klein RA, Morgan AC. Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-Dalton melanoma-associated antigen. J. Natl. Cancer Inst. 1985; 74: 299–306.

    PubMed  CAS  Google Scholar 

  66. Buraggi GL, Callegar L, Mariani G, Cascinelli N, Attilli A, Bombardieri E, Terno G, Plassio G, Dovis M, Mazzuca N, PG, Scassellati GA, Ferrone S. Imaging with I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab’)2 fragments. Cancer Res. 1985; 45: 3378–87.

    PubMed  CAS  Google Scholar 

  67. Larson SM, Carrasquillo JA, McGuffin RW, Krohn KA, Ferens JM, Hill LO, Beaumier PL Reynolds JC, Hellstrom K-E, Hellstrom I. Use of I-131-labeled murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiol. 1985; 155: 487–92.

    CAS  Google Scholar 

  68. Halpern S, Dillman RO, Witztum KF, Shega JF, Hagan PL, Burrows WM, Dillman JB, Clutter ML, Sobol RE, Frinke JM, Bartholemew RM, David GS, Carol DJ Radio-immunodetection of melanoma utilizing 111In 96, 5 monoclonal antibody: a preliminary report. Radiol. 1985; 155: 493–99.

    CAS  Google Scholar 

  69. Murray JL, Rosenblum MG, Sobol RE, Bartholomew RM, Plager CE, Haynie TP, Jahns MF, Glenn HJ, Lamki L, Benjamin R, Papadopoulos N, Boddie AW, Frinke JM, David GS, Carlo DJ, Hersch EM. Radio-immuno-imaging in malignant melanoma with In-labeled monoclonal antibody 96.5. Cancer Res. 1985; 45: 2376–81.

    PubMed  CAS  Google Scholar 

  70. Larson SM, Carrasquillo JA, Krohn KA, McGuffin RW, Williams DL, Hellström I, Hellström K-E. Diagnostic imaging of malignant melanoma with radiolabeled antitumor antibodies. J. Amer. Med. Ass. (JAMA) 1983; 249: 811–12.

    Article  CAS  Google Scholar 

  71. Larson SM, Carrasquillo JA, Krohn KA, Brown JP, McGuffin RW, Ferens JM, Graham MM, Hill LD, Beaumier PL, Hellstrom K-E, Hellström I. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J. Clin. Invest. 1983; 72: 2101–14.

    Article  PubMed  CAS  Google Scholar 

  72. Rosenblum MG, Murray JL, Haynie TP, Glenn HJ, Jahns MF, Benjamin RS, Frincke JM, Carlo DJ, Hersch EM. Pharmacokinetics of IN-labeled anti p97 monoclona antibody in patients with metastatic malignant melanoma. Cancer Res. 1985; 45: 2382–86.

    PubMed  CAS  Google Scholar 

  73. Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclona IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA. 1985; 82: 1242–46.

    Article  PubMed  CAS  Google Scholar 

  74. Imai K, Pellegrino MA, Wilson BS, Ferrone S. Higher cytolytic efficiency of an IgG2a than of an IgGl monoclanal antibody reacting with the same (or spationally close) determinant on a human high-molecular-weight melanoma-associated antigen. Cell. Immunol. 1982; 72: 239–47.

    Article  PubMed  CAS  Google Scholar 

  75. Harper JR, Reisfeld RA. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonalantibody to a chondroitin sulfate proteoglycan. J. Natl. Caner Inst. 1983; 71: 259–63.

    CAS  Google Scholar 

  76. Schulz G, Bumol TF, Reisfeld RA. Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 1983; 80: 5407–11.

    Article  PubMed  CAS  Google Scholar 

  77. Bumol TF, Wang EQ, Reisfeld RA, Kaplan NO. Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. USa, 1985; 80: 529–33.

    Article  Google Scholar 

  78. Schulz G., Staffileno LK, Reisfeld RA, Dennert G. Eradication of established human melanoma tumors in nude mice by antibody-directed effects cells. J. Exp. Med. 1985; 161: 1315–25.

    Article  PubMed  CAS  Google Scholar 

  79. Herlyn D, Powe J, Ross AH, Herlyn M, Koprowski H. Inhibition of human tumor growth by IgG2a monoclonal antibodies correlates with antibody density on tumor cells. J. Immunol. 1985; 143: 1300–04.

    Google Scholar 

  80. Hellström I, Brankovan V, Hellström K-E. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc. Natl. Acad. Sci. USA, 1985; 82: 1499–02.

    Article  PubMed  Google Scholar 

  81. Katano M, Jien M, Irie RF. Human monoclonal antibody to ganglioside GD2-inhibited human melanoma xenograft. Eur. J. Cancer Clin. Oncol. 1984; 20: 1053–59.

    Article  PubMed  CAS  Google Scholar 

  82. Dippold WG, Knuth A, Meyer zum Buschenfelde K-H. Inhibition or human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res. 1984; 44: 806–10.

    PubMed  CAS  Google Scholar 

  83. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. Immunol. 1985; 82: 5155–59.

    CAS  Google Scholar 

  84. Lindmo T, Boven E, Mitchell JB, Morstyn G, Bunn PA. Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody. Cancer Res. 1985; 45: 5080–87.

    PubMed  CAS  Google Scholar 

  85. Casellas P, Brown JP, Gros O, Gros P, Hellström I, Jansen FK, Poncelet P, Roncucci R, Vidal H, Hellström K-E. Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int. J. Cancer 1982; 30: 437–43.

    Article  PubMed  CAS  Google Scholar 

  86. Matsui M, Nakanishi T, Noguchi T, Imai K, Yachi A, Ferrone S. Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin. Jpn. J. Cancer Res. (Gann). 1985; 76: 119–23.

    PubMed  CAS  Google Scholar 

  87. Kerbel RS, Man MS, Dexter D. A model of human cancer metastasis: extensive spontaneous and arteficial metastasis of a human pigmented melanoma and derived variant sublines in nude mice. J. Natl. Cancer Inst. 1984; 72: 93–101.

    PubMed  CAS  Google Scholar 

  88. Lockshin A, Giovanella BS, de Ipolyi PD, Williams Jr. LJ, Mendoza JT, Ockyim S, Stehlin Jr. JS. Exceptional lethality for nude mice of cells derived from a primary human melanoma. Cancer Res. 1985; 45: 345–60.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. J. Ruiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E-B. Broecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Vennegoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Ferrone
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology, University Medical Center, Nijmegen, The Netherlands

    Dirk J. Ruiter

  2. Department of Pathology, University Medical Center, Leiden, The Netherlands

    Gert Jan Fleuren  & Sven O. Warnaar  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1987 Martinus Nijhoff Publishers, Dordrecht

About this chapter

Cite this chapter

Ruiter, D.J., Broecker, EB., Vennegoor, C., Ferrone, S. (1987). Monoclonal Antibodies Recognizing Melanoma-Associated Antigens.. In: Ruiter, D.J., Fleuren, G.J., Warnaar, S.O. (eds) Application of Monoclonal Antibodies in Tumor Pathology. Developments in Oncology, vol 50. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-3299-9_8

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-3299-9_8

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-7981-5

  • Online ISBN: 978-94-009-3299-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation